BOYDSense (an Alpha MOS subsidiary), selected among the 12 most innovative French Medtech by the National Union of the Medical Technology Industry (SNITEM)

BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN : FR0013421286 ALNEO), has been selected by a jury from the National Union of the Medical Technology Industry (SNITEM) in ordert o participate to the 8th edition of the start-ups day, organized on April 4th at la Cité des Sciences. This event brings together all start-ups related to Medtech and awards, at the end of a day of conferences and workshops, a jury prize and a public prize, among 12 start-ups.

BOYDSense’s flagship innovation is Lassie, a non-invasive platform for monitoring blood glucose levels through breath analysis for people with diabetes. This method replaces fingertip micropuncture and transforms chronic disease monitoring with a painless, reliable and compact device.

« We are very proud that our solution will be honored on this day, as it makes a significant difference in the lives of people with diabetes. The health and comfort of people suffering from chronic diseases are at the heart of our priorities. Lassie will be presented to the Medtech community on April 4th » said Ben Delhey, CEO of BOYDSense.

The 12 start-ups were selected according to four criteria :
• The potential of the solution,
• The potential of the target market,
• The quality of the team,
• The proposed business plan.

About BOYDSense

BOYDSense, Inc. is a medical technology company developing affordable, non-invasive tools for measuring critical biomarkers via exhaled breath. Its mission is to build the platform for anywhere, anytime biosignature capture and display to help consumers better manage their conditions. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense’s first product under development, the g-Sense Breath Meter, is an affordable handheld device that allows people with diabetes to accurately measure blood glucose values through breath-based VOCs without the cost, pain, and social stigma associated with conventional fingerstick glucose testing. BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.

For more information, please visit: